Market Research Report
ROI in Pharmaceutical R&D: How to Halt the Decline
|Published by||BCC Research||Product code||919383|
|Published||Content info||196 Pages
Delivery time: 1-2 business days
|ROI in Pharmaceutical R&D: How to Halt the Decline|
|Published: December 13, 2019||Content info: 196 Pages||
The global orphan drugs market should reach $315.6 billion by 2024 from $127.5 billion in 2017 at a compound annual growth rate (CAGR) of 13.8% for the forecast period of 2017 to 2024.
The global infectious disease treatments market should reach $117.2 billion by 2024 from $64.8 billion in 2017 at a CAGR of 8.8% for the forecast period of 2017 to 2024.
The global cardiovascular drugs market should reach $153.7 billion by 2024 from $141.1 billion in 2017 at a CAGR of 1.2% for the forecast period of 2017 to 2024.
The scope of this study begins with the challenges facing biotech and pharmaceutical companies today. It goes on to discuss regulatory approval processes in various countries, how these are changing, and the knock-on effects which the pharma/biotech companies will have to address. The report then reviews several key financial ratios, then discusses how to maximize clinical development success rate. We then go into how machine learning (ML) and artificial intelligence (AI), along with Big Data, are disrupting the pharma/biotech industry, in a positive way. The report then reviews the global markets for treatments for selected cancers, chronic diseases, cardiovascular disease, neurological diseases, infectious diseases and rare diseases. Chapter 15 discusses how companies need to deeply integrate ML, AI and Big Data into drug discovery and clinical testing-or risk falling behind the competition. The report wraps up with summaries of selected companies active in these spaces and beginning to utilize digital tools in R&D.